Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in Psoriasis Vulgaris and PsA with Inadequate Response to Anti-IL23
NCT05499416Phase 4Withdrawn
- Sponsor
- Innovaderm Research
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 4 trial of bimekizumab in Psoriasis vulgaris (PV), psoriatic arthritis (PsA), sponsored by Innovaderm Research. Planned start Jan 2023; status: withdrawn.
02
Drugs
bimekizumab
03
Conditions
Psoriasis vulgaris (PV)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05499416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05499416.